Four-year gut disease treatment trial seeks lasting relief
NCT ID NCT05177835
Summary
This study follows people with moderate to severe ulcerative colitis who are already taking the experimental drug ABX464. It aims to check the long-term safety and effectiveness of taking 25mg of ABX464 once daily for up to 54 months. The research will monitor patients for side effects and track whether their symptoms and gut inflammation stay under control over several years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital
Antwerp, Belgium
-
CHU Nantes - Hôtel Dieu
Nantes, France
-
CHU Saint Etienne - Hôpital Nord
Saint-Etienne, France
-
Centre Hospitalier Universitaire De Montpellier
Montpellier, France
-
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, France
-
Centro Medico Teknon
Barcelona, Spain
-
Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
Wroclaw, Poland
-
Centrum Medyczne Oporow
Wroclaw, Poland
-
Centrum Medyczne Plejady
Krakow, Poland
-
Cliniq s.r.o.
Bratislava, Slovakia
-
Communal non-commercial enterprise "Cherkasy Regional Hospital of Cherkasy regional council"
Cherkasy, Ukraine
-
Communal non-commercial enterprise "Khmelnytska Regional Hospital" of Khmelnytskiy regional council
Khmelnytskyi, Ukraine
-
DRC Gyogyszervizsgalo Kozpont Kft.
Balatonfüred, Hungary
-
Endomed s.r.o
Vranov nad Topľou, Slovakia
-
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
-
GASTRO I, s.r.o.
Prešov, Slovakia
-
Goethe University Frankfurt
Frankfurt, Germany
-
Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház I. Belgyógyászat
Győr, Hungary
-
Humanitas Mirasole S.p.A.
Rozzano, Italy
-
IRCCS Ospedale Sacro Cuore Don Calabria
Verona, Italy
-
Institut des MICI
Neuilly-sur-Seine, France
-
Kliničko bolnički centar Zvezdara
Belgrade, Serbia
-
LexMedica
Wroclaw, Poland
-
Medical Network Sp. z o.o.
Warsaw, Poland
-
Medical University of Vienna
Vienna, Austria
-
Medicome Sp. z o. o.
Oświęcim, Poland
-
Medizinische Hochschule Hannover
Hanover, Germany
-
Medizinische Universitaet Innsbruck
Innsbruck, Austria
-
Nemocnice Slany
Slaný, Czechia
-
Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj sp. p
Lublin, Poland
-
Opšta bolnica "Đorđe Joanović" Zrenjanin Odsek za gastroenterologiju
Zrenjanin, Serbia
-
Ośrodek Badań Klinicznych "METABOLICA"
Tarnów, Poland
-
Samodzielny PZOZ w Lecznej
Łęczna, 21-010, Poland
-
Santa Sp. z o.o.
Warsaw, Poland
-
Semmelweis University
Budapest, Hungary
-
South Edmonton Gastroenterology
Edmonton, Canada
-
Splosna Bolnisnica Murska Sobota
Murska Sobota, Slovenia
-
Splošna bolnišnica Celje
Celje, Slovenia
-
Studiengesellschaft BSF UG (haftungsbeschraenkt)
Halle, Germany
-
Termedia Sp. z o.o (NSZOZ Termedica - Centrum Badan Klinicznych)
Poznan, Poland
-
Trialmed CRS
Piotrkow Trybunalski, Poland
-
UZ Leuven
Leuven, Belgium
-
Univerzitetni klinični center Maribor
Maribor, Slovenia
-
Vasutegeszseguegyi Nonprofit Koezhasznu Kft.
Debrecen, Hungary
-
Wojskowy Szpital Kliniczny w Lublinie
Lublin, Poland
Conditions
Explore the condition pages connected to this study.